Pan Canadian Pharmaceutical Alliance

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The May 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Three negotiations were completed, while three more were closed for a total of 215 completed/closed negotiations; Three new drug products have initiated pCPA negotiations, for a total of 42 active negotiations; One new drug product was added to the “No pCPA…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The April 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Seven new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; One negotiation was completed (none closed), for a total of 208 joint completed/closed negotiations; and No new drug products were added to the “No pCPA Negotiations”…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The March 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Four new drug products have initiated pCPA negotiations, for a total of 40 active negotiations; Two negotiations have been completed (none closed), for a total of 207 joint completed/closed negotiations; and One new drug product was added to the…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The February 28, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Seven new drug products have initiated pCPA negotiations, for a total of 39 active negotiations; Five negotiations have been completed/closed, for a total of 205 joint completed/closed negotiations; and No new drug products were added to the “No pCPA…

pCPA Monthly Trends & Insights – January 2018   The January 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Two new drug products have initiated pCPA negotiations, for a total of 36 active negotiations; Four negotiations have been completed/closed, for a total of 200 joint completed/closed negotiations; and No new drug products were added to the “No…

MORSE Consulting has prepared a Year in Review infographic to highlight some key metrics surrounding the pCPA’s activities in 2017. This analysis highlights completed negotiations broken down in a number of different ways as well as several initiation and negotiation timing measures. MORSE concludes the analysis with our overall perspective on pCPA’s activities over the past year.   Click here to view full-size infographic   Click here to view full-size…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The December 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Five new drug products have initiated pCPA negotiations, for a total of 36 active negotiations; Eight negotiations have been completed/closed, for a total of 196 joint completed/closed negotiations; and One new drug product was added to…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The November 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Four new drug products have initiated pCPA negotiations, for a total of 39 active negotiations; Eleven negotiations have been completed/closed, for a total of 188 joint completed/closed negotiations; and One new drug product was added to…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The October 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Two new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; Seven negotiations have been completed/closed, for a total of 177 joint completed/closed negotiations; and No new drug products were added to…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The September 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Six new drug products have initiated pCPA negotiations, for a total of 51 active negotiations; Two negotiations have been completed/closed, for a total of 170 joint completed/closed negotiations; and One new drug product was added to…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The August 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Six new drug products have initiated pCPA negotiations, for a total of 47 active negotiations; Five negotiations have been completed, for a total of 168 joint negotiations; and One new drug product was added to the…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update   The latest update as of July 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO update are as follows: Seven new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations Three negotiations have been completed since the last update, for a total of 163 joint…

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Updates   The latest update as of June 30, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO update are as follows: Six new drug products have initiated pCPA negotiations since the last update, for a total of 42 active negotiations Seven negotiations have been completed since the last update, for a total of 160 joint…